T1	Participants 110 165	heart failure patients with preserved ejection fraction
T2	Participants 287 336	patients with preserved ejection fraction (HFpEF)
T3	Participants 444 494	chronic outstanding and stable patients with HFpEF
T4	Participants 658 733	L-arginine group (n = 15; 8 g/day); and the citrulline malate group (n = 15
T5	Participants 1339 1358	patients with HFpEF
